Peter Halfmann

This study designs a reoriented H5 hemagglutinin vaccine to induce stem-directed antibodies, providing cross-protective immunity against diverse influenza A viruses.

This paper develops a CRISPR-Cas3-based diagnostic platform for emerging RNA viruses, enabling rapid assay design and deployment with high sensitivity and portability.

This study shows bovine-derived H5N1 viruses face evolutionary constraints in ferrets, limiting adaptation for efficient mammalian transmission despite robust replication.

This study shows that transgenic Syrian hamsters expressing human DPP4 support MERS-CoV infection and direct contact transmission, making them a useful model for studying the virus.

The paper identifies two broadly neutralizing antibodies against Ebolavirus glycoprotein and shows that one enhances the neutralization breadth and potency of other antibodies.

This study shows that CR3022-like antibodies can be evolved in vivo through vaccination to neutralize SARS-CoV-2 and related viruses by enhancing affinity and breadth.

The paper describes the enantioselective resolution of a chemical probe targeting CHIKV nsP2 helicase, showing potent antiviral activity for one enantiomer and low activity for the other.

The paper identifies RNA-protein interactomes of SARS-CoV-2 genomic and subgenomic RNAs, revealing new host factors involved in viral replication and antiviral defense.

The paper compares SARS-CoV-2 antigenicity across assays and in human and animal model sera, finding similar immunodominance patterns and antigenic maps but differences in titer magnitude and assay-specific fold change.